The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2025Planning for a LRRK2 Platform Trial
Study Rationale: The therapeutic landscape for LRRK2-related Parkinson’s disease (LRRK2-PD) is rapidly evolving, creating an urgent need to evaluate emerging treatments. Given the distinct clinical...
-
Summer 2025 RFA: Personalized Approaches for Understanding, Assessing and Improving Gait in Parkinson’s Disease Research Program, 2026Sensing-Enabled Directional Deep Brain Stimulation of the Cuneiform Nucleus for Levodopa-Resistant Freezing of Gait in Parkinson’s Disease
Study Rationale:
Freezing of gait (FOG) is one of the most disabling symptoms of Parkinson’s disease. People with FOG may suddenly feel like their feet are “stuck” to the ground, especially when...
-
Summer 2025 RFA: Personalized Approaches for Understanding, Assessing and Improving Gait in Parkinson’s Disease Research Program, 2026Precision Mapping of Somato-Cognitive Action Network (SCAN) Pathophysiology in Parkinson’s Disease Gait Disturbance
Study Rationale:
Parkinson’s Disease (PD) is a neurodegenerative disorder caused by dysfunction in specific brain systems. We recently discovered a new brain system called the Somato-Cognitive...
-
Bridge Funding for Disrupted Neurodegenerative Research Grant Program, 2026Dissecting Non-canonical Basal Ganglia Output Circuitry Modulating Movement
Study Rationale:
Multiple brain structures work together to coordinate movement. We have found a new pathway that modulates movement through a brainstem structure that dies in Parkinson’s disease (PD)...
-
Summer 2025 RFP: Accelerating Biological Understanding and Translational Approaches for PD Program - Biology, 2026Inhibition of Acid Ceramidase as a Therapy for GBA1-associated PD
Study Rationale:
Mutations in the GBA1 gene are the highest known risk factor for Parkinson’s disease (PD). In GBA1-associated PD (GBA1/PD), an enzyme in the lysosome of the cell...
-
Spring 2025 RFA: Molecular MRI Biomarker Program, 2026Development of Next Generation Metabolic MR Imaging to Probe Molecular Mechanisms and Treatment Response in PD Patients Across Disease Stages
Study Rationale: There is a great unmet clinical need for more effective therapies to treat Parkinson Disease (PD). Successful clinical translation of new disease-modifying treatments can be...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.